Lawsuit Alleges Securities Fraud Against Chemours Company
Investors are urged to contact Schall, Brown & Schwartz LLP regarding a securities fraud lawsuit against The Chemours Company. The complaint alleges the company made false and misleading statements regarding product demand and financial guidance.
The national shareholder rights litigation firm Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit filed against The Chemours Company (NYSE: CC). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, concerning statements made between February 20, 2026, and August 4, 2026.
According to the complaint, Chemours allegedly overstated demand for its Opteon products, attributing a slowdown to prior year overselling. The company's fiscal guidance for 2026 is also described as unreliable. The lawsuit contends that these statements were materially misleading, and investors suffered damages when the truth emerged.
SBS encourages shareholders who purchased Chemours stock during the specified class period and incurred losses to contact the firm. The firm notes that while an opportunity exists to be appointed lead plaintiff, it is not required to participate in any recovery. The deadline for interested parties to contact the firm is December 7, 2026.
Schall, Brown & Schwartz LLP focuses on securities class action lawsuits and shareholder rights litigation, representing investors globally.